AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients

Bilek, Heval Can; Deveci, Aydın; TANYEL, ESRA

doi:10.14744/hnhj.2020.82335

AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients

Heval Can BİLEK, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Samsun, Türkiye)

Aydın DEVECİ, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Samsun, Türkiye)

Esra TANYEL (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Samsun, Türkiye)

Haydarpaşa Numune Medical Journal

4 1

Yıl: 2022 Cilt: 62 Sayı: 3 Sayfa Aralığı: 271 - 275 Metin Dili: İngilizce DOI: 10.14744/hnhj.2020.82335 İndeks Tarihi: 30-09-2022

AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients

Öz:

Introduction: Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) continues to be a serious worldwide public health problem despite widespread efforts to control the disease. Today, with the introduction of high-ac- tive antiretroviral therapy, AIDS-related mortality rates are significantly reduced and life expectancy for HIV-infected patients has increased. In this study, it was aimed to evaluate AIDS-defining illnesses during the clinical course of HIV infection and the effects of immune status on clinical outcomes. Methods: The medical records of HIV infected patients who were followed up between January 2005 and November 2018 were retrospectively investigated. Results: During the study period, 336 HIV-infected patients were followed up. Among 336 patients, 45 (13.3%) had experi- enced one or more, a total of 59 episodes of AIDS-defining illnesses during follow-ups. Of 45 patients who had experienced AIDS-defining illnesses, 42 (93,3%) were male, the mean age was 41.1±9.7 years and 12 of them were found to have died when this study conducted. The median count of CD4 T lymphocytes and the mean age at the time of diagnosis of 33 alive and 12 died patients were 106 cells/mm3, 40.1±9.9 years, and 94 cells/mm3, 43.9±8.5 years, respectively. There was no statis- tically significant difference between the median count of CD4 T lymphocytes and the mean age of alive and died patients. The most common AIDS-defining illness was Pneumocystis jirovecii pneumonia with 28.8%. The most common diagnosed cause of mortality was AIDS-related carcinomas with 33%. Discussion and Conclusion: These findings reveal that the most important preventive measure for survival in HIV-infected patients is the early diagnosis of the disease and the initiation of antiretroviral therapy before the emergence of AIDS-defin- ing illnesses due to severe immune deficiency.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Bhatti AB, Usman M, Kandi V. Current scenario of HIV/AIDS, treatment options, and major challenges with compliance to antiretroviral therapy. Cureus 2016;8:e515.
2. Global HIV & AIDS statistics — 2018 fact sheet. UNAIDS. Available at: http://www.unaids.org/en/resources/docu- ments/2018/unaids -data-2018. Accessed Jan 5, 2019.
3. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2019 – 2018 data. Stockholm: ECDC; 2019. Available at: https://www.ecdc.europa.eu/en/publications-data/hivaids- surveillance-europe-2019-2018-data. Accessed Dec 5, 2019.
4. Republıc Of Turkey Mınıstry Of Health. HIV-AIDS Statistics 2019. Available at: https://hsgm.saglik.gov.tr/tr/bulasici- hastaliklar/hiv-aids/hiv-aids-liste/hıv-aids-istatislik.html. 2018. Accessed Jan 5, 2019.
5. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Bat- tegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013;14:195–207.
6. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, et al. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: Evidence from a large European observa- tional cohort collaboration. Int J Epidemiol 2012;41:433–45.
7. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012;26:335–43.
8. Castilla J, Sobrino P, De La Fuente L, Noguer I, Guerra L, Parras F. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: Consequences for AIDS incidence. AIDS 2002;16:1945–51.
9. Centers for Disease Control and Prevention (CDC). Revised surveillance case definition for HIV infection--United States, 2014. MMWR Recomm Rep. 2014;63:1–10.
10. Podlasin RB, Wiercinska-Drapalo A, Olczak A, Beniowski M, Smiatacz T, Malolepsza E, et al. Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002. Infec- tion 2006;34:196–200.
11. Thorsteinsson K, Ladelund S, Jensen-Fangel S, Larsen MV, Jo- hansen IS, Katzenstein TL, et al. Impact of gender on the risk of AIDS-defining illnesses and mortality in Danish HIV-1-in- fected patients: A nationwide cohort study. Scand J Infect Dis 2012;44:766–75.
12. Reinhardt SW, Reinhardt SW, Spec A, Meléndez J, Alonzo Cor- don A, Ross I, et al. AIDS-defining illnesses at initial diagnosis of HIV in a large guatemalan cohort. Open Forum Infect Dis 2017;4:ofx249.
13. Coelho L, Cardoso SW, Amancio RT, Moreira RI, Campos DP, Veloso VG, et al. Trends in AIDS-defining opportunistic ill- nesses incidence over 25 years in Rio de Janeiro, Brazil. PLoS One 2014;9:e98666.
14. Kaya S, Yılmaz G, Erensoy Ş, Arslan M, Köksal İ. Retrospective analysis of 36 HIV/AIDS cases. Klimik J 2011;24:11–6.
15. Ozdemir B, Yetkin MA, Bastug A, But A, Aslaner H, Akinci E, et al. Evaluation of epidemiological, clinical, and laboratory fea- tures and mortality of 144 HIV/AIDS cases in Turkey. HIV Clin Trials 2018;19:69–74.
16. Taşdelen-Fışgın N, Tanyel E, Sarıkaya-Genç H, Tülek N. Evalua- tion of HIV/AIDS cases. Klimik J 2009;22:18–20.
17. Erbay A, Kayaaslan B, Akıncı E, Öngürü P, Eren SS, Gözel G, et al. Evaluation of epidemiological, clinical and laboratory features of HIV/AIDS cases. Flora Derg 2009;14:36–42.
18. Kaptan F, Örmen B, Türker N, El S, Ural S, Vardar İ, et al. Retro- spective evaluation of 128 cases infected with human immun- odeficiency virus. Turkiye Klinikleri J Med Sci 2011;31:525–33.
19. Hay JW, Osmond DH, Jacobson MA. Projecting the medical costs of AIDS and ARC in the United States. J Acquir Immune Defic Syndr (1988) 1988;1:466–85.
20. Lundberg BE, Davidson AJ, Burman WJ. Epidemiology of pneu- mocystis carinii pneumonia in an era of effective prophylaxis: The relative contribution of non-adherence and drug failure. AIDS 2000;14:2559–66.
21. Mirani G, Williams PL, Chernoff M, Abzug MJ, Levin MJ, Seage GR 3rd, et al. Changing trends in complications and mortality rates among US youth and young adults with HIV infection in the era of combination antiretroviral therapy. Clin Infect Dis 2015;61:1850–61.
22. Lowe DM, Rangaka MX, Gordon F, James CD, Miller RF. Pneu- mocystis jirovecii pneumonia in tropical and low and middle income countries: A systematic review and meta-regression. PLoS One 2013;8:e69969.
23. Sayan M, Hınçal E, Şanlıdağ T, Kaymakamzade B, Sa'ad FT, Baba IA. Dynamics of HIV/AIDS in Turkey from 1985 to 2016. Qual Quant 2018;52(Suppl 1):711–23.
24. Erdinç FŞ, Dokuzoğuz B, Ünal S. Changing trends in the epi- demiology of Turkey. In: 30th IUSTI Europe Conference (15- 17 September 2016, Budapest, Hungary) Abstract Book. UK: International Union Against Sexually Transmitted Infections; 2016. p.115–6.
25. Horsburgh CR Jr, Pozniak A. Epidemiology of tuberculosis in the era of HIV. AIDS 1993;7(1 Suppl):S109–14.
26. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Rav- iglione MC, et al. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009–21.
27. Republic Of Turkey Ministry Of Health. Tuberculosis report 2018 in Turkey. Available at: https://hsgm.saglik.gov.tr/depo/ birimler/tuberkuloz_db/dosya/raporlar/Tu_rkiye_de_Verem_ Savas_2018_Raporu_kapakl_.pdf. Accessed Jan 5, 2019.
28. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009;23:2337–45.
29. Bedimo R, Chen RY, Accortt NA, Raper JL, Linn C, Allison JJ, et al. Trends in AIDS-defining and non-AIDS-defining malignan- cies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004;39:1380–4.
30. Allardice GM, Hole DJ, Brewster DH, Boyd J, Goldberg DJ. Inci- dence of malignant neoplasms among HIV-infected persons in Scotland. Br J Cancer 2003;89:505–7.
31. Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D'Souza G, et al. Cumulative incidence of cancer among persons with HIV in North America: A cohort study. Ann Intern Med 2015;163:507–18.
32. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011;117:1089–96.
33. Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010;24:1537–48.
34. Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. Non-AIDS-defining deaths and immunode- ficiency in the era of combination antiretroviral therapy. AIDS 2009;23:1743–53.
35. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretro- viral therapy: New York City. Ann Intern Med 2006;145:397– 406.

APA	Bilek H, Deveci A, TANYEL E (2022). AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients. , 271 - 275. 10.14744/hnhj.2020.82335
Chicago	Bilek Heval Can,Deveci Aydın,TANYEL ESRA AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients. (2022): 271 - 275. 10.14744/hnhj.2020.82335
MLA	Bilek Heval Can,Deveci Aydın,TANYEL ESRA AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients. , 2022, ss.271 - 275. 10.14744/hnhj.2020.82335
AMA	Bilek H,Deveci A,TANYEL E AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients. . 2022; 271 - 275. 10.14744/hnhj.2020.82335
Vancouver	Bilek H,Deveci A,TANYEL E AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients. . 2022; 271 - 275. 10.14744/hnhj.2020.82335
IEEE	Bilek H,Deveci A,TANYEL E "AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients." , ss.271 - 275, 2022. 10.14744/hnhj.2020.82335
ISNAD	Bilek, Heval Can vd. "AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients". (2022), 271-275. https://doi.org/10.14744/hnhj.2020.82335

APA	Bilek H, Deveci A, TANYEL E (2022). AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients. Haydarpaşa Numune Medical Journal, 62(3), 271 - 275. 10.14744/hnhj.2020.82335
Chicago	Bilek Heval Can,Deveci Aydın,TANYEL ESRA AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients. Haydarpaşa Numune Medical Journal 62, no.3 (2022): 271 - 275. 10.14744/hnhj.2020.82335
MLA	Bilek Heval Can,Deveci Aydın,TANYEL ESRA AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients. Haydarpaşa Numune Medical Journal, vol.62, no.3, 2022, ss.271 - 275. 10.14744/hnhj.2020.82335
AMA	Bilek H,Deveci A,TANYEL E AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients. Haydarpaşa Numune Medical Journal. 2022; 62(3): 271 - 275. 10.14744/hnhj.2020.82335
Vancouver	Bilek H,Deveci A,TANYEL E AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients. Haydarpaşa Numune Medical Journal. 2022; 62(3): 271 - 275. 10.14744/hnhj.2020.82335
IEEE	Bilek H,Deveci A,TANYEL E "AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients." Haydarpaşa Numune Medical Journal, 62, ss.271 - 275, 2022. 10.14744/hnhj.2020.82335
ISNAD	Bilek, Heval Can vd. "AIDS-Defining Illnesses and Mortality in a Cohort of 336 HIV- Infected Patients". Haydarpaşa Numune Medical Journal 62/3 (2022), 271-275. https://doi.org/10.14744/hnhj.2020.82335